Novel Medical Countermeasure for Organophosphorus Intoxication: Connection to Alzheimer’s Disease and Dementia

Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics

Volumn , Issue , 2007, Pages 219-232

  Pereira, Edna F R ^a   Burt, David R ^a   Aracava, Yasco ^a   Kan, Robert K ^b   Hamilton, Tracey A ^b   Romano, James A ^c   Adler, Michael ^b   Albuquerque, Edson X ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61349089693     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420046625-16     Document Type: Chapter

References (74)

1. Abou-Donia, M.B., Organophosphorus ester-induced chronic neurotoxicity, Arch. Environ. Health, 58, 484, 2003.
2. Albuquerque, E.X. et al., Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents, Proc. Natl. Acad. Sci. U.S.A., 103, 13220, 2006.
3. Arias, E. et al., Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors, Neuropharmacology, 46, 103, 2004.
4. Arias, E. et al., Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors, J. Pharmacol. Exp. Ther., 315, 1346, 2005.
5. Bajgar, J., Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment, Adv. Clin. Chem., 38, 151, 2004.
6. Baldi, I. et al., Neurodegenerative diseases and exposure to pesticides in the elderly, Am. J. Epidemiol., 157, 409, 2003.
7. Bhagat, Y.A. et al., Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion- and T2-weighted magnetic resonance imaging, Neurotoxicology, 26, 1001, 2005.
8. Cannard, K., The acute treatment of nerve agent exposure, J. Neurol. Sci., 249, 86, 2006.
9. Capsoni, S., Giannotta, S., and Cattaneo, A., Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice, Proc. Natl. Acad. Sci. U.S.A., 99, 12432, 2002.
10. Chung, J.A. and Cummings, J.L., Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: characteristics and treatment, Neurol. Clin., 18, 829, 2000.
11. Couzin, J., Clinical trials. New rule triggers debate over best way to test drugs, Science, 299, 1651, 2003.
12. Coyle, J. and Kershaw, P., Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease, Biol. Psychiatry, 49, 289, 2001.
13. Coyle, J.T., Price, D.L., and DeLong M.R., Alzheimer’s disease: a disorder of cortical cholinergic innervation, Science, 219, 1184, 1983.
14. Damodaran, T.V. et al., Gene expression profiles of the rat brain both immediately and 3 months following acute sarin exposure, Biochem. Pharmacol., 71, 497, 2006.
15. Deshpande, S.S. et al., Effectiveness of physostigmine as a pretreatment drug for protection of rats from organophosphate poisoning, Fundam. Appl. Toxicol., 6, 566, 1986.
16. DiGiovanni, C., Domestic terrorism with chemical or biological agents: psychiatric aspects, Am. J. Psychiatry, 156, 1500, 1999.
17. Duysen, E.G. et al., Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality, J. Pharmacol. Exp. Ther., 299, 528, 2001.
18. Fricke, R.F. et al., Efficacy of tacrine as a nerve agent pretreatment, Drug Chem. Toxicol., 17, 15, 1994.
19. Geerts, H., Indicators of neuroprotection with galantamine, Brain Res. Bull., 64, 519, 2005.
20. Geoghegan, J. and Tong, J.L., Chemical warfare agents, Contin. Educ. Anaesth. Crit. Care Pain, 6, 230, 2006.
21. Goedert, M. and Spillantini, M.G., A century of Alzheimer’s disease, Science, 314, 777, 2006.
22. Grunwald, J. et al., Huperzine A as a pretreatment candidate drug against nerve agent toxicity, Life Sci., 54, 991, 1994.
23. Heinrich, M. and Lee Teoh, H., Galanthamine from snowdrop-the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge, J. Ethnopharmacol., 92, 147, 2004.
24. Hellstrom-Lindahl, E. et al., Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain, Brain Res. Mol. Brain Res., 66, 94, 1999.
25. Jamal, G.A., Long-term neurotoxic effects of organophosphate compounds, Adverse Drug React. Toxicol. Rev., 14, 85, 1995.
26. Jamal, G.A., Neurological syndromes of organophosphorus compounds, Adverse Drug React. Toxicol. Rev., 16, 133, 1997.
27. Kamel, F. et al., Neurobehavioral performance and work experience in Florida farmworkers, Environ. Health Perspect., 111, 1765, 2003.
28. Karalliedde, L. and Senanayake, N., Organophosphorus insecticide poisoning, Br. J. Anaesth., 63, 736, 1989.
29. Kihara, T. et al., Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 325, 976, 2004.
30. Kilimov, N., Effect of Nivalin on audiogenic seizures in mice, Dokl. Bulg. Acad. Nauk., 18, 287, 1965.
31. Lallement, G. et al., Review of the value of huperzine as pretreatment of organophosphate poisoning, Neurotoxicology, 23, 1, 2002a.
32. Lallement, G. et al., Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity, Drug Chem. Toxicol., 25, 309, 2002b.
33. Layish, I. et al., Pharmacologic prophylaxis against nerve agent poisoning, Isr. Med. Assoc. J., 7, 182, 2005.
34. Lleo, A., Greenberg, S.M., and Growdon, J.H., Current pharmacotherapy for Alzheimer’s disease, Ann. Rev.Med., 57, 513, 2006.
35. Loy, C. and Schneider, L., Galantamine for Alzheimer’s disease and mild cognitive impairment, Cochrane Database Syst. Rev., 1, CD001747, 2006.
36. Maelicke, A. and Albuquerque, E.X., New approach to drug therapy of Alzheimer’s dementia, Drugs Disc.Today, 1, 53, 1996.
37. Maelicke, A. et al., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease, Biol. Psychiatry, 49, 279, 2001.
38. Marrs, T.C., The role of diazepam in the treatment of nerve agent poisoning in a civilian population, Toxicol.Rev., 23, 145, 2004.
39. Mashkovsky, M.D. and Kruglikova-Lvova, R.P., On the pharmacology of the new alkaloid galantamine, Farmakologia Toxicologia (Moscow), 14, 27, 1951 (in Russian).
40. Maxwell, D.M. and Brecht, K.M., The role of carboxylesterase in species variation of oxime protection against soman, Neurosci. Biobehav. Rev., 15, 135, 1991.
41. Maxwell, D.M. et al., Effect of carboxylesterase inhibition on carbamate protection against soman toxicity, J. Pharmacol. Exp. Ther., 246, 986, 1988.
42. Maxwell, D.M. et al., Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds? Arch. Toxicol., in press, 2006.
43. Newmark, J., Nerve agents: pathophysiology and treatment of poisoning, Semin. Neurol., 24, 185, 2004a.
44. Newmark, J., Therapy for nerve agent poisoning, Arch. Neurol., 61, 649, 2004b.
45. Newmark, J., Nerve agents, Neurol. Clin., 23, 623, 2005.
46. Nicolson, R., Craven-Thuss, B., and Smith, J., A prospective, open-label trial of galantamine in autistic disorder, J. Child. Adolesc. Psychopharmacol., 16, 621, 2006.
47. Nordberg, A., Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications, Biol.Psychiatry, 49, 200, 2001.
48. Okonjo, K.O., Kuhlmann, J., and Maelicke, A., A second pathway of activation of the Torpedo acetylcholine receptor channel, Eur. J. Biochem., 200, 671, 1991.
49. Pearson, V.E., Galantamine: a new alzheimer drug with a past life, Ann. Pharmacother., 35, 1406, 2001.
50. Pereira, E.F.R. et al., Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons, J. Pharmacol. Exp. Ther., 265, 1474, 1993.
51. Pereira, E.F.R. et al., Physostigmine and galanthamine: probes for a novel binding site on the a4b2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells, J. Pharmacol. Exp. Ther., 270, 768, 1994.
52. Pereira, E.F.R. et al., Unconventional ligands and modulators of nicotinic receptors, J. Neurobiol., 53, 479, 2002.
53. Perry, E. et al., Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases, Eur. J.Pharmacol., 393, 215, 2000.
54. Plaitakis, A. and Duvoisin, R.C., Homer’s moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning, Clin. Neuropharmacol., 6, 1, 1983.
55. Rickett, D.L., Glenn, J.F., and Beers, E.T., Central respiratory effects versus neuromuscular actions of nerve agents, Neurotoxicology, 7, 225, 1986.
56. Robertson, E.D. and Mucke, L., 100 Years and counting: prospects for defeating Alzheimer’s disease, Science, 314, 781, 2006.
57. Sabbagh, M.N. et al., Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer’s disease and dementia with Lewy bodies, J. Neural Transm., 108, 1149, 2001.
58. Samochocki, M. et al., Galantamine is an allosterically potentiating ligand of the human a4b2 nAChR, Acta Neurol. Scand. Suppl., 176, 68, 2000.
59. Santos, M.D. et al., The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system, Mol. Pharmacol., 61, 1222, 2002.
60. Schrattenholz, A. et al., Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine, Eur. J.Biochem., 216, 671, 1993.
61. Schrattenholz, A. et al., Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands, Mol. Pharmacol., 49, 1, 1996.
62. Schroder, B. et al., Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide, J. Biol. Chem., 269, 10407, 1994.
63. Schubert, M.H., Young, K.A., and Hicks, P.B., Galantamine improves cognition in schizophrenic patients stabilized on risperidone, Biol. Psychiatry, 50, 521, 2006.
64. Schwendimann, R.N., Burton, E., and Minagar, A., Management of myasthenia gravis, Am. J. Ther., 12, 262, 2005.
65. Shaw, K.P. et al., The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex, Mol. Pharmacol., 28, 527, 1985.
66. Sherby, S.M. et al., Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor, Mol. Pharmacol., 27, 343, 1985.
67. Shih, T.M., Duniho, S.M., and McDonough, J.H., Control of nerve agent-induced seizures is critical for neuroprotection and survival, Toxicol. Appl. Pharmacol., 188, 69, 2003.
68. Sramek, J.J., Frackiewicz, E.J., and Cutler, N.R., Review of the acetylcholinesterase inhibitor galanthamine, Expert Opin. Investig. Drugs, 9, 2393, 2000.
69. Storch, A. et al., Physostigmine, galanthamine and codeine act as ʼnoncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells, Eur. J. Pharmacol., 290, 207, 1995.
70. Tokuda, Y. et al., Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack, Resuscitation, 68, 193, 2006.
71. Wevers, A. et al., Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein, Eur.J. Neurosci., 11, 2551, 1999.
72. Wiener, S.W. and Hoffman, R.S., Nerve agents: a comprehensive review, J. Int. Care Med., 19, 22, 2004.
73. Yanagisawa, N., Morita, H., and Nakajima, T., Sarin experiences in Japan: acute toxicity and long-term effects, J. Neurol. Sci., 249, 76, 2006.
74. Zhang, Z.W., Coggan, J.S., and Berg, D.K., Synaptic currents generated by neuronal acetylcholine receptors sensitive to a-bungarotoxin, Neuron, 17, 1231, 1996.